This brand name is authorized in United States
The drug RHOPRESSA contains one active pharmaceutical ingredient (API):
|
1
Netarsudil
UNII VL756B1K0U - NETARSUDIL MESYLATE
|
|
Netarsudil, a Rho kinase inhibitor, is believed to reduce intraocular pressure (IOP) by increasing outflow of aqueous humor. Studies in animal and man suggest that the main mechanism of action is increased trabecular outflow. These studies also suggest that netarsudil lowers IOP by reducing episcleral venous pressure. |
Below package inserts are available for further reading:
| Title | Information Source | Document Type | |
|---|---|---|---|
| RHOPRESSA Ophthalmic solution | FDA, National Drug Code (US) | MPI, US: SPL/PLR |
This drug has been assigned below unique identifiers within the countries it is being marketed:
| Country | Identification scheme | Identifier(s) |
|---|---|---|
| Country: US | FDA, National Drug Code | Identifier(s): 70727-497 |
© All content on this website, including data entry, data processing, decision support tools, "RxReasoner" logo and graphics, is the intellectual property of RxReasoner and is protected by copyright laws. Unauthorized reproduction or distribution of any part of this content without explicit written permission from RxReasoner is strictly prohibited. Any third-party content used on this site is acknowledged and utilized under fair use principles.
